147 results on '"Peacock, Stuart J."'
Search Results
2. Use of chemotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study
3. Are patients with cancer at higher risk of COVID-19-related death? A systematic review and critical appraisal of the early evidence
4. The risk of contracting SARS-CoV-2 or developing COVID-19 for people with cancer: A systematic review of the early evidence
5. A perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada
6. Vaccine nationalism will persist: global public goods need effective engagement of global citizens
7. The FACT-8D, a new cancer-specific utility algorithm based on the Functional Assessment of Cancer Therapies-General (FACT-G): a Canadian valuation study
8. Early-Phase Clinical Trials and Reimbursement Submissions to the Pan-Canadian Oncology Drug Review
9. The Cost-Effectiveness of High-Risk Lung Cancer Screening and Drivers of Program Efficiency
10. Efficiency in the provision of health care for end stage renal failure
11. Public perspectives on disinvestments in drug funding: results from a Canadian deliberative public engagement event on cancer drugs
12. Public engagement in priority-setting: Results from a pan-Canadian survey of decision-makers in cancer control
13. Resource Utilization and Costs during the Initial Years of Lung Cancer Screening with Computed Tomography in Canada
14. Trade-offs, fairness, and funding for cancer drugs: key findings from a deliberative public engagement event in British Columbia, Canada
15. Severity as an independent determinant of the social value of a health service
16. Do Quality-Adjusted Life Years Take Account of Lost Income? Evidence from an Australian Survey
17. Supplier-induced demand: re-examining identification and misspecification in cross-sectional analysis
18. Health-related quality of life data collected in chimeric antigen receptor T-cell (CAR-T) therapy clinical trials
19. Cost-Effectiveness of the Addition of Rituximab to CHOP Chemotherapy in First-Line Treatment for Diffuse Large B-Cell Lymphoma in a Population-Based Observational Cohort in British Columbia, Canada
20. Societal preferences for the return of incidental findings from clinical genomic sequencing: a discrete-choice experiment
21. Gynecologic Cancer Risk and Genetics: Informing an Ideal Model of Gynecologic Cancer Prevention.
22. Determinants of Preferences for Genetic Counselling in Jewish Women
23. Supplier-Induced Demand: Reconsidering the Theories and New Australian Evidence
24. Priority setting in health care using multi-attribute utility theory and programme budgeting and marginal analysis (PBMA)
25. Impact of TAILORx on chemotherapy prescribing and 21-gene recurrence score-guided treatment costs in a population-based cohort of patients with breast cancer.
26. Priority setting in healthcare: towards guidelines for the program budgeting and marginal analysis framework
27. Effect of Early Palliative Care on End-of-Life Health Care Costs: A Population-Based, Propensity Score--Matched Cohort Study.
28. Does an increase in the doctor supply reduce medical fees? An econometric analysis of medical fees across Australia
29. Trajectory of End-of-Life Pain and Other Physical Symptoms among Cancer Patients Receiving Home Care.
30. Construction of the descriptive system for the assessment of quality of life AQoL-6D utility instrument
31. A randomized controlled trial of Human Papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL Trial)
32. Trajectory of psychosocial symptoms among home care patients with cancer at end-of-life.
33. Quality of life and socioeconomic indicators associated with survival of myeloid leukemias in Canada.
34. Comparing Childhood Cancer Care Costs in Two Canadian Provinces.
35. Health-related quality of life in oncology drug reimbursement submissions in Canada: A review of submissions to the pan-Canadian Oncology Drug Review.
36. The Girls-Only HPV Vaccination Program in British Columbia, Canada: A Qualitative Study Exploring Expert Informants' Perspectives of Input From the Public
37. COST-EFFECTIVENESS IMPACTS CANCER CARE FUNDING DECISIONS IN BRITISH COLUMBIA, CANADA, EVIDENCE FROM 1998 TO 2008.
38. Cost-Effectiveness Analysis of Using Loss of Heterozygosity to Manage Premalignant Oral Dysplasia in British Columbia, Canada.
39. Economic impact of genomic diagnostics for intermediate-risk acute myeloid leukaemia.
40. A Time-Trend Economic Analysis of Cancer Drug Trials.
41. 'Real-world' health care priority setting using explicit decision criteria: a systematic review of the literature.
42. Genomic testing to determine drug response: measuring preferences of the public and patients using Discrete Choice Experiment (DCE).
43. Exploring Colposcopists' Attitudes Towards Use of HPV Testing as a Primary Screening Tool for Cervical Cancer in British Columbia
44. A randomized controlled trial of HumanPapillomavirus (HPV) testing for cervical cancerscreening: trial design and preliminary results(HPV FOCAL Trial).
45. Priority setting in practice: what is the best way to compare costs and benefits?
46. Supplier-Induced Demand.
47. Public attitudes and values in priority setting.
48. Modelling uncertainty in survival and cost-effectiveness is vital in the era of gene therapies: the case of axicabtagene ciloleucel.
49. The EORTC QLU-C10D: The Canadian Valuation Study and Algorithm to Derive Cancer-Specific Utilities From the EORTC QLQ-C30.
50. Genomic testing to determine drug response: measuring preferences of the public and patients using Discrete Choice Experiment (DCE)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.